| Identification | Back Directory | [Name]
10H-1,3-Dioxolo[4,5-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-8,11(7H,13H)-dione, 7-ethyl-7-hydroxy-14-[4-(trifluoromethyl)phenyl]-, (7S)- | [CAS]
794512-88-2 | [Synonyms]
10H-1,3-Dioxolo[4,5-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-8,11(7H,13H)-dione, 7-ethyl-7-hydroxy-14-[4-(trifluoromethyl)phenyl]-, (7S)- | [Molecular Formula]
C28H19F3N2O6 | [MOL File]
794512-88-2.mol | [Molecular Weight]
536.46 |
| Hazard Information | Back Directory | [Uses]
FLQY2 is a camptothecin analog that exhibits outstanding antitumor efficacy against various solid tumors. FLQY2 possesses both in vitro and in vivo anti-pancreatic cancer activity, inhibiting cell proliferation, colony formation, inducing apoptosis, and causing cell cycle arrest at nanomolar concentrations[1][2]. | [References]
[1] Wang W, et al. Biological impact and therapeutic potential of a novel camptothecin derivative (FLQY2) in pancreatic cancer through inactivation of the PDK1/AKT/mTOR pathway[J]. Bioorganic Chemistry, 2024, 148: 107436. DOI:10.1016/j.bioorg.2024.107436
[2] Wang Y, et al. Preparation of a camptothecin analog FLQY2 self-micelle solid dispersion with improved solubility and bioavailability[J]. Journal of Nanobiotechnology, 2022, 20(1): 402. DOI:10.1186/s12951-022-01596-2 |
|
|